Photo by thommilkovic from unsplash
P304, HIV Drug Therapy 2016. Glasgow, October 23–26, 2016. 8 Elliot E, Wang X, Pagani N et al. Pharmacokinetics of dolutegravir in people living with HIV over the age of… Click to show full abstract
P304, HIV Drug Therapy 2016. Glasgow, October 23–26, 2016. 8 Elliot E, Wang X, Pagani N et al. Pharmacokinetics of dolutegravir in people living with HIV over the age of 60. Abstract 432, CROI 2017, Seattle, Washington. 9 Cattaneo D, Minisci D, Cozzi V et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Abstract P303, HIV Drug Therapy 2016. Glasgow, October 23–26, 2016. 10 Gervasoni C, Riva A, Capetti A et al. Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat. Abstract 410, CROI 2017, Seattle, Washington. 11 Cattaneo D, Rizzardini G, Gervasoni C. Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. AIDS 2017; 31: 867–868. 12 De Boer MG, Brinkman K. Recent observations on intolerance of dolutegravir: differential causes and consequences. AIDS 2017; 31: 868–869.432, CROI 2017, Seattle, Washington. 9 Cattaneo D, Minisci D, Cozzi V et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Abstract P303, HIV Drug Therapy 2016. Glasgow, October 23–26, 2016. 10 Gervasoni C, Riva A, Capetti A et al. Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat. Abstract 410, CROI 2017, Seattle, Washington. 11 Cattaneo D, Rizzardini G, Gervasoni C. Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. AIDS 2017; 31: 867–868. 12 De Boer MG, Brinkman K. Recent observations on intolerance of dolutegravir: differential causes and consequences. AIDS 2017; 31: 868–869. 13 Yagura H, Watanabe D, Nakauchi T. Effect of dolutegravir plasma concentration on central nervous system side effects. Abstract 426, CROI 2017, Seattle, Washington.426, CROI 2017, Seattle, Washington. 14 Fettiplace A, Stainsby C, Winston A et al. Psychiatric symptoms in patients receiving dolutegravir. JAIDS 2017; 74: 423–431. © 2017 British HIV Association HIV Medicine (2018), 19, e60--e61 Letter to the Editor e61
Journal Title: HIV Medicine
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!